November 22nd 2024
A new study shows that COVID-19 infection significantly increases the risk of exacerbation in patients with myasthenia gravis (MG).
Diagnostic Criteria for Hidradenitis Suppurativa May Overlook Pediatric Patients
November 16th 2022More than a third (42.8%) of pediatric patients with hidradenitis suppurativa did not meet all major diagnostic criteria at the time of diagnosis, particularly due to failure to fulfill the recurrence interval criterion (2 or more lesions within 6 months).
Read More
Providers Must Educate Congress, CMS on Reality of Oncology Practice Finances, Dr Kavita Patel Says
November 14th 2022Former Obama administration official Kavita Patel, MD, MS, told a gathering of the OneOncology Physician Leadership Conference that policy leaders and members of Congress need input on the realities of oncology practice finances.
Read More
Topical Calcineurin Inhibitors for AD Not Associated With Cancer
November 14th 2022Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a systematic review and meta-analysis.
Read More
OneOncology’s Clinical Pathways Covers Best Practices for 90% of Patients, Says Dr Ted Arrowsmith
November 13th 2022The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.
Watch
Dr Timothy Murphy: Strong Communication Is Necessary for Practices Stocking Multiple Biosimilars
November 13th 2022With multiple biosimilars approved for a reference product and different payers preferring particular products, communication between the clinical pharmacy team and the managed care team is crucial, said Timothy Murphy, MD, FACP, medical oncologist/hematologist with Rocky Mountain Cancer Centers.
Watch
Dr Joseph Alvarnas: Cancer Care Equity Act Meets the Needs of Patients With Advanced Disease
November 12th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on how the California Cancer Care Equity Act will allow oncologists to escalate the care of patients with advanced cancers toward established centers that can better meet their needs, as well as implications from the decision to exclude genomic testing coverage in the bill.
Watch
Dr Davey Daniel Hits the High Points of the OneOncology Annual Conference
November 12th 2022The OneOncology Annual Conference is being held November 11-13 in Nashville, Tennessee, and brings together practice leaders, physicians, and advanced practice providers to discuss the business of oncology and scientific advancements, explained Davey Daniel, MD, chief medical officer of OneOncology.
Watch
Dr Melissa O'Connor: Further Research Needed for Technology Use in Home Health
November 12th 2022Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in community and home health nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, spoke on the early use of technology in assessing older adults in the home setting and what research is required to improve best practices for their use.
Watch
CDI-Related Mortality Risk Greater in Hospitalized Children With Cystic Fibrosis
November 11th 2022Pediatric patients who developed coexisting Clostridioides difficile infection (CDI) while hospitalized for cystic fibrosis exhibited greater mortality risk, length of stay, and cost compared with those without cooccuring CDI.
Read More
Dr Liz Lightstone on Emerging Treatment Options, Unmet Needs in Lupus Nephritis
November 11th 2022Liz Lightstone, MBBS, PhD, FRCP, professor of renal medicine for the faculty of medicine, Imperial College London, discussed recently approved therapeutic options for patients with lupus nephritis and what unmet needs persist in the management of the disease.
Watch
Social Impact of Hidradenitis Suppurativa Associated With Worse QOL, Mental Health Burden
November 11th 2022Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.
Read More
Dr Jeffrey Patton on Setting Standards of Care Through OneOncology’s Clinical Pathways Program
November 11th 2022Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Watch
More than 100 health care organizations signed a HHS climate resilience pledge; linking patients in addiction treatment with a primary care practitioner is linked with improved long-term health outcomes; older men and women with weak grip strength may have accelerated biological aging.
Read More
Simvastatin Ineffective as Disease-Modifying Therapy for Intermediate Parkinson Disease
November 10th 2022Patients with intermediate and mild Parkinson disease, defined by a Hoehn & Yahr stage of 3 or less, experienced an additional deterioration in motor function with simvastatin compared with placebo while not taking medication at 24 months.
Read More
Investigating Real-World Effectiveness of Disease-Modifying Therapies in AD by Skin Type
November 10th 2022Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.
Read More
Examining Risk Factors, Prodromal Features of Parkinson Disease
November 9th 2022Several known risk factors and prodromal features were associated with Parkinson disease, including traumatic brain injury and alcohol misuse, along with other comorbidities such as skin and gastrointestinal disorders.
Read More
Phase 3 Study Shows Live Biotherapeutic Significantly Reduces CDI Recurrence
November 8th 2022A phase 3 study showed Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, to be safe and significantly reduce recurrence of Clostridioides difficile infection (CDI) after antibiotic treatment, with a sustained response achieved through 6 months.
Read More
Daniel E. Weiner, MD, MS, board certified nephrologist and lead navigator at Tufts Clinical and Translational Science Institute, spoke on the limitations and future potential of value-based payment systems for chronic kidney disease (CKD), including the End-Stage Renal Disease (ESRD) Treatment Choices (ETC) Model and the Kidney Care Choices (KCC) Models.
Watch
Curtis Warfield, MS, senior quality analyst, Indiana State Department of Health, and regional leader of National Kidney Foundation's Kidney Advocacy Committee, spoke on limitations regarding the current process of educating and managing lifestyle interventions for patients with chronic kidney disease (CKD), and how nephrologists can better integrate these strategies.
Watch
Nephrology Director Shares Ups, Downs of Participating in Kidney Care First
November 6th 2022It has been 3 years since new kidney care payment models were announced by HHS, and at a session at Kidney Week 2022, the associate division director of nephrology at the University of Alabama at Birmingham described his organization’s participation in Kidney Care First, one of the value-based care models announced in 2019.
Read More
Jen Gunter, MD, obstetrician and gynecologist, author, and specialist in chronic pain medicine and vulvovaginal disorders, spoke on the change in perspective regarding the medical and scientific community's role in dispelling health care misinformation on social media and in the press.
Watch
Jennifer Green, MD, professor of medicine at Duke University School of Medicine, member of Duke Clinical Research Institute, and EMPA-KIDNEY collaborator, discussed findings of the EMPA-KIDNEY trial presented at Kidney Week 2022, which showed a 28% improvement for patients with chronic kidney disease (CKD) on empagliflozin, whether in reduced mortality from cardiovascular disease or progression of CKD.
Watch
Dr Ray Bignall II on Understanding the Environment Patients Live In
November 4th 2022Access to care remains a key issue when trying to deliver equitable kidney health care to patients, explained O.N. Ray Bignall II, MD, assistant chief diversity and health equity officer at Nationwide Children’s Hospital.
Watch